Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 6/20 | 0.36 |
| ▸ | CNR1 | P21554 | 5/20 | 0.36 |
| ▸ | BCHE | P06276 | 5/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932380 | 0.83 | PARP1 (0.40) | AURKACCNA2CDK2CCNA1PARP1 | |
| SCHEMBL3816429 | 0.79 | PARP1 (0.37) | PARP1CNR2CNR1KDM4CCFD | |
| SCHEMBL3840072 | 0.78 | KDM4C (0.37) | AURKACCNA2CDK2CCNA1PARP1 | |
| SCHEMBL2931203 | 0.74 | KDM4E (0.38) | CCNA2CDK2CCNA1PARP1KDM4E | |
| SCHEMBL3843011 | 0.74 | CNR2 (0.47) | PARP1CNR2CNR1 | |
| SCHEMBL7550775 | 0.72 | CNR2 (0.62) | PARP1CNR2CNR1KDM4E | |
| SCHEMBL3843932 | 0.72 | CNR2 (0.40) | CNR2CNR1 | |
| SCHEMBL3839667 | 0.72 | KMT2A (0.42) | KDM4EHSD17B10 | |
| SCHEMBL28079408 | 0.70 | ELANE (0.49) | PARP1KDM4ECFD | |
| SCHEMBL3843007 | 0.69 | SRC (0.39) | PARP1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828207-B1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | AURKA 1493/4885CCNA2 3091/4885CDK2 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.